AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15529259 — intervention group
Group type: COMPARATOR
Intervention: No TCF
Number of subjects: 3496
Study 15529259 — intervention group
Group type: COMPARATOR
Intervention: TCF
Number of subjects: 3496
Study 11855773 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 9
Study 11855773 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch release relaxation
Number of subjects: 9
Study 11855773 — intervention group
Group type: COMPARATOR
Intervention: Cognitive imagery relaxation
Number of subjects: 9
Study 9831140 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preservation techniques (formaldehyde) for tympano-ossicular allograft preservation
Number of subjects: 5
Study 9831140 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group (washed, dried, and stored in sterile tubes at -70 degrees without further processing)
Number of subjects: 5
Study 8085587 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1%
Number of subjects: 10
Study 8085587 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac vehicle
Number of subjects: 10
Study 2486579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meperidine 12.5 mg
Number of subjects: 0
Study 2486579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meperidine 25 mg
Number of subjects: 0
Study 2486579 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-temperature epidural lidocaine
Number of subjects: 0
Study 2486579 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-temperature epidural lidocaine
Number of subjects: 0
Study 2486579 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 7374 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 12
Study 7374 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 30911113 — intervention group
Group type: EXPERIMENTAL
Intervention: Short telomere length
Number of subjects: 620
Study 29185604 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy (PT)
Number of subjects: 44
Study 29185604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PT)
Number of subjects: 44
Study 25865294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 25
Study 23819226 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion apparatus
Number of subjects: 100
Study 23819226 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (2HRZE/4HRE)
Number of subjects: 100
Study 21542675 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 269
Study 21542675 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 269
Study 19852040 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg MMPD
Number of subjects: 354
Study 19852040 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MMPD
Number of subjects: 354
Study 19852040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 16757129 — intervention group
Group type: COMPARATOR
Intervention: 68 Gy
Number of subjects: 468
Study 16757129 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 468
Study 14740231 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 null genotype
Number of subjects: 0
Study 14740231 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTT1 null genotype
Number of subjects: 0
Study 14740231 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GSTM1 and GSTT1 null genotypes
Number of subjects: 0
Study 14740231 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 polymorphism
Number of subjects: 0
Study 15629284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-enucleation radiation
Number of subjects: 1003
Study 15629284 — intervention group
Group type: COMPARATOR
Intervention: Enucleation alone
Number of subjects: 1003
Study 10863964 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1 genotype positive patients
Number of subjects: 323
Study 10863964 — intervention group
Group type: COMPARATOR
Intervention: IL‐1 genotype negative patients
Number of subjects: 323
Study 10863964 — intervention group
Group type: COMPARATOR
Intervention: IL‐1 genotype negative subjects
Number of subjects: 323
Study 9197352 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV disease
Number of subjects: 141
Study 9197352 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 141
Study 9197352 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal reexploration (excluding retransplantation)
Number of subjects: 141
Study 9197352 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient age ≤ 16 years
Number of subjects: 141
Study 9197352 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of units of blood products administered during transplantation
Number of subjects: 141
Study 9197352 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased pretransplant renal function (estimated by creatinine clearance)
Number of subjects: 141
Study 9197352 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for retransplantation
Number of subjects: 141
Study 7968324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine (0.2 mg/kg) with spinal tetracaine (12‐16 mg)
Number of subjects: 60
Study 3512006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix (sodium and meglumine ioxaglate)
Number of subjects: 0
Study 3512006 — intervention group
Group type: COMPARATOR
Intervention: Meglumine iothalamate (ionic medium)
Number of subjects: 0
Study 3142220 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 52
Study 3142220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31903724 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 1012
Study 31903724 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL (IGlar U100)
Number of subjects: 1012
Study 30367884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FA) insert (0.18 mg)
Number of subjects: 129
Study 30367884 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 129
Study 28963915 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (Herceptin® SC) 600 mg fixed dose followed by intravenous trastuzumab (Herceptin®) 8 mg/kg loading, 6 mg/kg maintenance doses every 3 weeks.
Number of subjects: 488
Study 28963915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous trastuzumab (Herceptin®) 8 mg/kg loading, 6 mg/kg maintenance doses every 3 weeks followed by subcutaneous trastuzumab (Herceptin® SC) 600 mg fixed dose.
Number of subjects: 488
Study 25999771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored neck muscle conditioning program (6-week exercise regime, performed 3 times a week)
Number of subjects: 34
Study 25999771 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal training and playing)
Number of subjects: 34
Study 25999771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored neck muscle conditioning program
Number of subjects: 34
Study 22704520 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal plain polysaccharide vaccine
Number of subjects: 0
Study 20930212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm training with rhythmic auditory cueing (BATRAC)
Number of subjects: 111
Study 20930212 — intervention group
Group type: COMPARATOR
Intervention: Dose‐matched therapeutic exercises (DMTE)
Number of subjects: 111
Study 20930212 — intervention group
Group type: EXPERIMENTAL
Intervention: BATRAC
Number of subjects: 111
Study 19321290 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Course (CDSMC)
Number of subjects: 216
Study 19321290 — intervention group
Group type: COMPARATOR
Intervention: Waiting‐List Control Group (WLCG)
Number of subjects: 216
Study 19321290 — intervention group
Group type: COMPARATOR
Intervention: Comparison Group (CG)
Number of subjects: 216
Study 17141354 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine and aspart
Number of subjects: 60
Study 17141354 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin and aspart
Number of subjects: 60
Study 15099940 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 microg, two capsules, four times daily)
Number of subjects: 31
Study 11371744 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective randomized trials (PRTs)
Number of subjects: 168
Study 11371744 — intervention group
Group type: COMPARATOR
Intervention: Not enrolled in PRTs
Number of subjects: 168
Study 11371744 — intervention group
Group type: EXPERIMENTAL
Intervention: PRTs
Number of subjects: 168
Study 9811154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.025-0.4 mg/day
Number of subjects: 2700
Study 9811154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg/day
Number of subjects: 2700
Study 9811154 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin
Number of subjects: 2700
Study 7915025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapiprazole
Number of subjects: 30
Study 7915025 — intervention group
Group type: COMPARATOR
Intervention: Control (nontreated eyes)
Number of subjects: 30
Study 3406455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy neutrons alone
Number of subjects: 32
Study 3406455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined photon-low energy neutron treatment regimen (mixed beam)
Number of subjects: 32
Study 3406455 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy neutrons alone
Number of subjects: 32
Study 3406455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron radiotherapy (overall)
Number of subjects: 32
Study 3406455 — intervention group
Group type: COMPARATOR
Intervention: Conventional photon and/or electron treatment
Number of subjects: 32
Study 31782131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion membrane (HAM) placed around the neurovascular bundle and vesicourethral anastomosis during radical prostatectomy.
Number of subjects: 328
Study 31782131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 328
Study 30890552 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg siltuximab
Number of subjects: 85
Study 30890552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 27197603 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power intervention delivered by teachers over a 6-month period
Number of subjects: 164
Study 27197603 — intervention group
Group type: COMPARATOR
Intervention: Standard academic curriculum (Control)
Number of subjects: 164
Study 26298296 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination at 20 μg (for children < 10 years) or 40 μg (for children > 10 years) at time 0, 1, and 6 months.
Number of subjects: 78
Study 26298296 — intervention group
Group type: COMPARATOR
Intervention: Control group received HBV vaccination at 10 μg (for children < 10 years) or 20 μg (for children > 10 years) at time 0, 1, and 6 months.
Number of subjects: 78
Study 23371919 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadobenate dimeglumine
Number of subjects: 68
Study 23371919 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mmol/kg gadopentetate dimeglumine
Number of subjects: 68
Study 21600559 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS cholecystectomy
Number of subjects: 0
Study 21600559 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic cholecystectomy (LC)
Number of subjects: 0
Study 19366816 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 120
Study 19366816 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 120
Study 19366816 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ischemic skin lesions
Number of subjects: 120
Study 19366816 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ulcerations or gangrene
Number of subjects: 120
Study 19366816 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological arterial disease score
Number of subjects: 120
Study 16679934 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenic diet
Number of subjects: 19
Study 16679934 — intervention group
Group type: COMPARATOR
Intervention: FDA food safety guidelines
Number of subjects: 19
Study 15286527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 59
Study 15286527 — intervention group
Group type: COMPARATOR
Intervention: NCEP diet (National Cholesterol Education Program Step II)
Number of subjects: 59
Study 11282756 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma
Number of subjects: 0
Study 11282756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis
Number of subjects: 0
Study 11282756 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 0
Study 11282756 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 0
Study 11282756 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 0
Study 11282756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild asthma
Number of subjects: 0
Study 9783191 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA therapy for 4 weeks before LH-RH analogue injection
Number of subjects: 44
Study 9783191 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA therapy for 2 weeks before LH-RH analogue injection
Number of subjects: 44
Study 9783191 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA pretreatment
Number of subjects: 44
Study 9783191 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA therapy
Number of subjects: 44
Study 7873847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral body autograft technique
Number of subjects: 46
Study 7873847 — intervention group
Group type: COMPARATOR
Intervention: Modified Smith-Robinson technique
Number of subjects: 46
Study 3416247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubbler oxygenating system
Number of subjects: 0
Study 3416247 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane oxygenating system
Number of subjects: 0
Study 3416247 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (Shiley-Buckberg system)
Number of subjects: 0
Study 3416247 — intervention group
Group type: COMPARATOR
Intervention: Nonoxygenated crystalloid cardioplegia
Number of subjects: 0
Study 3416247 — intervention group
Group type: COMPARATOR
Intervention: Oxygenated crystalloid cardioplegia
Number of subjects: 0
Study 3416247 — intervention group
Group type: COMPARATOR
Intervention: Membrane and blood delivery systems
Number of subjects: 0
Study 30680617 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month program of weekly aerobic exercises associated with nutritional counseling (n = 41)
Number of subjects: 61
Study 30680617 — intervention group
Group type: COMPARATOR
Intervention: Usual care with nutritional counseling (n = 20, one withdrawal)
Number of subjects: 61
Study 28614869 — intervention group
Group type: EXPERIMENTAL
Intervention: MA212 (40 mL daily)
Number of subjects: 92
Study 28614869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 28614869 — intervention group
Group type: EXPERIMENTAL
Intervention: MA212
Number of subjects: 92
Study 26293069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol
Number of subjects: 60
Study 26293069 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale scores at rest
Number of subjects: 60
Study 26293069 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale scores during coughing
Number of subjects: 60
Study 26293069 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 60
Study 26293069 — intervention group
Group type: COMPARATOR
Intervention: Overall satisfaction degree
Number of subjects: 60
Study 24163616 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% HP
Number of subjects: 120
Study 24163616 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% HP with light activation
Number of subjects: 120
Study 24163616 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% HP with manganese gluconate
Number of subjects: 120
Study 24163616 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% HP
Number of subjects: 120
Study 24163616 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% HP with light activation
Number of subjects: 120
Study 24163616 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% HP with manganese gluconate
Number of subjects: 120
Study 21373969 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (TMZ) and 13‐cis retinoic acid (13‐cRA) treatment
Number of subjects: 32
Study 21373969 — intervention group
Group type: COMPARATOR
Intervention: Retrospective comparison to TMZ-treated group in NOA-04 phase-III trial
Number of subjects: 32
Study 19423623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B phototherapy at home using a TL‐01 home phototherapy unit
Number of subjects: 196
Study 19423623 — intervention group
Group type: COMPARATOR
Intervention: Standard narrowband ultraviolet B phototherapy in an outpatient setting
Number of subjects: 196
Study 17344769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication adherence assessment via telephone questionnaire
Number of subjects: 295
Study 17344769 — intervention group
Group type: COMPARATOR
Intervention: Age groups comparison
Number of subjects: 295
Study 17344769 — intervention group
Group type: COMPARATOR
Intervention: Race and gender comparison
Number of subjects: 295
Study 17344769 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with poor adherence
Number of subjects: 295
Study 15478486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel restoration with resin-based composites
Number of subjects: 38
Study 15478486 — intervention group
Group type: COMPARATOR
Intervention: Class II resin-based composite restorations
Number of subjects: 38
Study 11678747 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic local anaesthesia (LA)
Number of subjects: 157
Study 11678747 — intervention group
Group type: COMPARATOR
Intervention: No anaesthesia
Number of subjects: 157
Study 9128029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg (2 ml of lidocaine 2%) added to 180 mg of propofol (18 ml)
Number of subjects: 106
Study 9128029 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 ml) added to 180 mg of propofol (18 ml)
Number of subjects: 106
Study 9128029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg premixed with 180 mg propofol
Number of subjects: 106
Study 7946254 — intervention group
Group type: EXPERIMENTAL
Intervention: Choral responding and student-to-student responding in small groups
Number of subjects: 24
Study 3253231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity continuous exercise training (CE; 40 min at 50% VO2peak, 3 days/week)
Number of subjects: 0
Study 3253231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise training (IE: 10 x 2 min at VO2peak, 3 days/week)
Number of subjects: 0
Study 3253231 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31758216 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational session on prescribing skills
Number of subjects: 34
Study 29631564 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine (group T)
Number of subjects: 70
Study 29631564 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline (group C)
Number of subjects: 70
Study 27040503 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFAs, 1 g three times a day for 18 months
Number of subjects: 281
Study 27040503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 25378225 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-grass pollen sublingual tablet
Number of subjects: 849
Study 22337597 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the right DLPFC
Number of subjects: 24
Study 22337597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS of the left DLPFC
Number of subjects: 24
Study 22337597 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 20228976 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic acid barrier
Number of subjects: 30
Study 20228976 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen membrane
Number of subjects: 30
Study 18525396 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha (1.5 microg/Kg every 20 days for 3 months) plus iron orally
Number of subjects: 41
Study 18525396 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus iron orally
Number of subjects: 41
Study 15671806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of azithromycin
Number of subjects: 363
Study 15671806 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of metronidazole +/‐ 500 mg of ciprofloxacin
Number of subjects: 363
Study 15671806 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 363
Study 12353340 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg, increased to 20 mg after 8 weeks
Number of subjects: 157
Study 12353340 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 10 mg, increased to 20 mg after 8 weeks
Number of subjects: 157
Study 10577635 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional antihypertensive drugs (atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or hydrochlorothiazide 25 mg plus amiloride 2.5 mg daily)
Number of subjects: 6614
Study 10577635 — intervention group
Group type: COMPARATOR
Intervention: Newer antihypertensive drugs (enalapril 10 mg or lisinopril 10 mg, or felodipine 2.5 mg or isradipine 2‐5 mg daily)
Number of subjects: 6614
Study 10577635 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional antihypertensive drugs
Number of subjects: 6614
Study 10577635 — intervention group
Group type: COMPARATOR
Intervention: Newer antihypertensive drugs
Number of subjects: 6614
Study 8741162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 0
Study 8741162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 0
Study 8741162 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 4 mg
Number of subjects: 0